Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2025 18:34 ET | Source: Alvotech

Alvotech Reports Record Results for 2024 and Provides Business Update

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in...
February 21, 2025 06:00 ET | Source: Alvotech

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of...
February 18, 2025 06:00 ET | Source: Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...